Thalidomide is an immunomodulator, anti-angiogenic agent, anti-cytokine, and anti-integrin. Alone or in combination with other drugs, thalidomide has also demonstrated anti-cachexin and anti-neoplastic properties.
Anorexia and cachexia are common symptoms of advanced cancer. Since certain cytokines also promote tumor growth, we may have a class of agents with palliative and anti-tumor benefits in combination with anti-neoplastics and anti-cytokines, such as thalidomide.
Abramson N, Stokes P: Ovarian and papillary-serous peritoneal carcinoma: pilot study using thalidomide. Proc ASCO. 2001; 20: 179b.
2.
Adlard JW: Thalidomide in the treatment of cancer. Anticancer Drugs. 2000; 11(10): 787-791.
3.
Argiles JM, Lopez-Soriano FJ: The role of cytokines in cancer cachexia. Med Res Rev. 1999; 19(3): 223-248.
4.
Barber MD, Ross JA, Voss AC, et al.: The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999; 81(1): 80-86.
5.
Boasberg PD, O’Day SJ, Weisberg M, et al.: Thalidomide induced cessation of weight loss and improved sleep in advanced cancer patients with cachexia. Proc ASCO. 2000; 19: 609a.
6.
Boyer MJ, Lim R, Clarke M, et al.: Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC)-a Cancer Therapeutics Research Group (CTRG) study. Proc ASCO. 2001; 20: 133b.
7.
Bruera E, Neumann CM, Pituskin E, et al.: Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncology. 1999; 10: 857-859.
8.
Calder K, Bruera E, Nuns G: Thalidomide for night sweats in patients with advanced cancer. Palliative Medicine. 2000; 14(1): 77-78.
9.
Clark TE, Edom N, Larson J, Lindsey LJ: Thalidomid (Thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety. 2001; 24(2): 87-117.
Davey PP, Ashrafian H: New therapies for heart failure: Is thalidomide the answer?QMJ. 2000; 93(5): 305-311.
12.
Deaner PB: The use of thalidomide in the management of severe sweating in patients with advanced malignancy: Trial report. Palliative Medicine. 14: 429-431.
13.
Diz Dios P, Sopena B, Cameselle J, et al.: Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers. Arch Otolaryngol Head Neck Surg. 2000; 126(1): 89-92.
14.
Eisen TG: Thalidomide in solid tumors: The London experience. Oncology. 2000; 12(13): 17-20.
15.
Eriksson T, Bjorkman S, Roth B, Hoglund P: Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man. J Pharmacy & Pharmacology. 2000; 52(7): 807-817.
16.
Eriksson T, Wallin R, Hoglund P, et al.: Low bioavailability of rectally administered thalidomide. American J Health-System Pharmacy. 2000; 57(17): 1607-1610.
17.
Escudier B, Lassau N, Couanet D, et al.: Phase II trial of thalidomide in renal carcinoma. Proc ASCO. 2001; 20: 180a.
18.
Fine HA, Maher EA, Wen PY, et al.: Phase II thalidomide and BCNUY in recurrent high-grade gliomas. Proc ASCO. 2001; 20: 55a.
19.
George A, Marziniak M, Schafers M, et al.: Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-terms effects on spinal cord dorsal horn met-enkephalin. Pain. 2000; 88(3): 267-275.
20.
Govindarajan R, Heaton KM, Broadwater R, et al.: Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000; 356: 566-567.
21.
Galani E, Grigoraki V, Kiamouris C, et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncology. 2000; 4(11): 97.
22.
Hamuryudan V, Mat C, Saip S, et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128(6): 443-450.
23.
Hoglund P, Ericksson T, Bjorkman S: A double-blind study of the sedative effects of the thalidomide enatiomers in humans. J Pharmacokinetics Biopharm. 1998; 26(4): 363-383.
24.
Hwu W, Panageas KS, Krown SE, et al.: Phase I study of temozolomide and thalidomide in the treatment of metastatic melanoma. Proc ASCO. 2001; 20: 357a.
25.
Herrstedt J: Prevention and management of mucositis in patients with cancer. Int J Antimicrobial Agents. 2000; 16(2): 161-163.
26.
Juliusson G, Celsing F, Turesson I, et. al.: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000; 109(1): 89-96.
27.
Kanbayashi T, Shimizu T, Takahasi Y, et al.: Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study. Sleep. 1999; 22(1): 113-115.
28.
Kaplan G, Thomas S, Fierer DS, et al.: Thalidomide for the treatment of AIDS-associated wasting. AIDS Research & Human Retroviruses. 2000; 16(14): 1345-1366.
29.
Keifer JA, Guttridge DC, Ashburner BP, Baldwin J: Inhibition of NF-kappa-B activity by thalidomide through suppression of I-kappa-B kinase activity. J Biol Chem. 2001; [in press].
30.
Kneller A, Raanani P, Hardan I, et al.: Therapy with thalidomide in refractory multiple myeloma patients—the revival of an old drug. Br J Haemetol. 2000; 108(2): 391-393.
31.
Lissoni P, Barni S, Mandala M, et al.: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status. Eur J Cancer. 1999; 35(12): 1688-1692.
32.
Lissoni P, Meregalli S, Fossati V, et al.A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori. 1994; 80(6): 464-467.
33.
Lissoni P, Paolorossi F, Ardizzoia A, et al.: A randomized study of chemotherapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical area. J Pineal Res. 1997; 23(1): 15-19.
34.
Lissoni P, Rovelli F, Malugani F, et al.: Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett. 2001; 22(1): 45-47.
35.
Little RF, Wyvill KM, Pluda JM, et al.: Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncology. 2000; 18(13): 2593-2602.
36.
Lokensgard JR, Hu S, van Fenema EM, et al.: Effect of thalidomide on chemokine production by human mircoglia. J Infectious Diseases. 2000; 182(3): 983-987.
37.
Marriott JB, Cookson S, Carlin E, et al.A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Research & Human Retroviruses. 1997; 13(18): 1625-1631.
38.
Neiger BL: The re-emergence of thalidomide: Results of scientific conference. Teratology. 2000; 62(6): 432-435.
39.
Noormohamed FH, Youle MS, Higgs CJ, et al.: Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Research & Human Retroviruses. 1999; 15(12): 1047-1052.
40.
Palakurthi SS, Fluckiger R, Aktas H, et al.: Inhibition of translation initiation mediates the anticancer effect of the n-3 polyun-saturated fatty acid eicosapentaenoic acid. Cancer Res. 2000; 60(11): 2919-2925.
41.
Peuckmann V, Fisch M, Bruera E: Potential novel uses of thalidomide. Drugs. 2000; 60(2): 273-292.
Rajkumar SV, Gertz MA, Dispenzieri A, et al.: Thalidomide therapy for previously untreated, smoldering, and relapse multiple myeloma. Proc ASCO. 2001; 20: 299a.
44.
Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Reviews. 2000; 25(5): 351-362.
45.
Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, et al.: Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis. 1999; 28(4): 892-894.
46.
Raza A, Lisak L, Little L, et al.: Summary and future direction of anti-tumor necrosis factor (TNF) therapies in myelodysplastic syndromes (MDS). Proc ASCO. 2001; 20: 237b.
47.
Richardson P, Hideshima T, Anderson K: Thalidomide: The revival of a drug with therapeutic promise in the treatment of cancer. Principles & Practice of Oncology. 2001; 15: 1-18.
48.
Sauer LA, Dauchy RT, Blask DE: Mechanism for the antitumor and anti-cachectic effects on n-3 fatty acids. Cancer Res. 2000; 60(18): 5289-5295.
49.
Sjak-Shie NN, Vescio RA, Berenson JR: Recent advances in multiple myeloma. Current Opinion in Hematology. 2000; 7(4): 241-246.
50.
Teo SK, Colburn WA, Thomas SD: Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol. 1999; 39(11): 1162-1168.
51.
Teo SK, Sheffler MR, Kook KA, et al.: Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharmaceutics & Drug Disposition. 2000; 21(1): 33-40.
52.
Thomas DA, Kantarjian HM: Current role of thalidomide in cancer treatment. Current Opinion in Oncology. 2000; 12: 564-573.
53.
Tisdale MJ: Wasting in cancer. J Nutr. 1999; 129(1S): 243S-246S.
54.
Tisdale MJ: Protein loss in cancer cachexia. Science. 2000; 289 (5488): 2293-2294.
55.
Watanabe S: Thalidomide (T) in the symptomatic treatment of cachexia in patients (pts) with terminal cancer. Proc ASCO. 1999; 18: 48a.
56.
Yam D, Peled A, Shinitzky M: Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother Pharmacol. 2001; 47(1): 34-40.
